Zevra Therapeutics (ZVRA) Non-Current Assets (2014 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Non-Current Assets came in at $48.6 million in Q1 2026, down 46.66% YoY from $91.1 million in Q1 2025, and down 21.24% on a QoQ basis from $61.7 million in Q4 2025.
Zevra Therapeutics (ZVRA) Non-Current Assets (2014 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 13 years of Non-Current Assets data on file, last reported at $48.6 million in Q1 2026.
- Quarterly Non-Current Assets fell 46.66% year-over-year to $48.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $185.3 million (down 48.37% YoY) and the FY2025 annual result came in at $61.7 million, down 32.98% from the prior year.
- Non-Current Assets declined to $48.6 million in Q1 2026, from $61.7 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $92.1 million in Q3 2024 to a low of -$105.8 million in Q1 2022.
- A 5-year average of $35.7 million and a median of $45.0 million in 2025 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets sank 4009.09% — and 2024, when it jumped 4577.96%.
- Tracing ZVRA's Non-Current Assets over 5 years: stood at $22.5 million in 2022, then soared by 279.41% to $85.4 million in 2023, then rose by 7.86% to $92.1 million in 2024, then tumbled by 32.98% to $61.7 million in 2025, then decreased by 21.24% to $48.6 million in 2026.
- The last three Non-Current Assets figures came in at $48.6 million (Q1 2026), $61.7 million (Q4 2025), and $45.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn | 51.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.41 Mn |
| Mar 31, 2026 | 48.61 Mn |
| Dec 31, 2025 | 61.72 Mn |
| Sep 30, 2025 | 45.00 Mn |
| Jun 30, 2025 | 29.94 Mn |
| Mar 31, 2025 | 91.14 Mn |
| Dec 31, 2024 | 92.10 Mn |
| Sep 30, 2024 | 92.11 Mn |
| Jun 30, 2024 | 83.52 Mn |
| Mar 31, 2024 | 88.39 Mn |
| Dec 31, 2023 | 85.39 Mn |
| Sep 30, 2023 | 1.97 Mn |
| Jun 30, 2023 | 2.09 Mn |
| Mar 31, 2023 | -104.28 Mn |
| Dec 31, 2022 | 22.51 Mn |
| Sep 30, 2022 | 34.42 Mn |
| Jun 30, 2022 | 37.25 Mn |
| Mar 31, 2022 | -105.78 Mn |
| Dec 31, 2021 | 17.89 Mn |
| Sep 30, 2021 | 2.56 Mn |